Skip to main
GRTS
GRTS logo

GRTS Stock Forecast & Price Target

GRTS Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 44%
Hold 22%
Sell 11%
Strong Sell 11%

Bulls say

Gritstone Bio Inc is advancing its pipeline of personalized cancer immunotherapies, showcasing promising clinical activity in its GRANITE product candidate, particularly among high-risk patients who experienced a significant reduction in progression risk and improved median progression-free survival rates. The company’s successful optimization of the vaccine cassette has demonstrated enhanced immune responses, which bodes well for future regulatory interactions with the FDA regarding the Phase 3 trial design. Additionally, the reported 100% manufacturing success rate for the GRTS samRNA vaccine and its effectiveness in producing durable immune responses in patients living with HIV underscores the potential of Gritstone’s immunotherapy platform and reinforces a positive outlook for the company’s future endeavors.

Bears say

Gritstone Bio faces a negative outlook primarily due to potential adverse safety and efficacy findings in current trials, which could necessitate downward revisions to financial projections. The possibility of a more complex and prolonged regulatory pathway for the company’s immunotherapy candidates further threatens to impact estimates unfavorably. Additionally, equity dilution from funding raises and associated warrants has prompted a reduction in the estimated value of the stock, highlighting the challenges the company faces in achieving a successful commercial trajectory.

GRTS has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 11% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gritstone Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gritstone Oncology Inc (GRTS) Forecast

Analysts have given GRTS a Hold based on their latest research and market trends.

According to 9 analysts, GRTS has a Hold consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gritstone Oncology Inc (GRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.